Semaglutide vs Tirzepatide: Which One Actually Wins?

Is tirzepatide actually better than semaglutide?

On average weight loss, yes. A trial called SURMOUNT-5 compared the two drugs directly. It randomly assigned 751 adults with obesity, but without diabetes, to one drug or the other for 72 weeks. The results appeared in the New England Journal of Medicine in May 2025.

People on tirzepatide lost an average of about 20% of their starting weight. People on semaglutide lost about 14%. Waists shrank more with tirzepatide too. About 20% of the tirzepatide group lost at least 30% of their weight, against about 7% on semaglutide.

That headline now needs an update. SURMOUNT-5 gave semaglutide at up to 2.4 mg, its top dose at the time. In March 2026, the FDA approved a higher 7.2 mg dose, sold as Wegovy HD.

In its own trial, called STEP UP, people on 7.2 mg lost about 18.7% of their weight. People on 2.4 mg lost 15.6%. People on a placebo, a dummy shot, lost 3.9%. That narrows the gap without closing it. The figures come from different trials with different people. No one has yet tested tirzepatide against the 7.2 mg dose.

The 7.2 mg dose is a step up, not a starting point. It is for people who have handled 2.4 mg for at least four weeks. Stomach side effects were more common at that strength.

These are trial averages, not a promise for any one woman. Results vary with dose, consistency, diet and biology. But tirzepatide still holds the only head-to-head win.

What's the real difference between semaglutide and tirzepatide?

The gap comes from how they work. Semaglutide acts on one target, the GLP-1 receptor. It slows the stomach, boosts insulin after meals and quiets hunger signals in the brain.

Tirzepatide does all of that and adds a second target, the GIP receptor. That seems to strengthen the effect on appetite, and possibly on how the body handles fat and blood sugar. This double action is the leading explanation for its edge in SURMOUNT-5. How much comes from the extra target, versus the doses tested, is still being studied.

Semaglutide vs tirzepatide side effects: is one easier to tolerate?

Both cause the same family of side effects, for the same reason. Slowing digestion is how they work, not an accident. Nausea, vomiting, diarrhea and constipation are the most common with both. They are usually worst in the first months and after each dose increase, then ease.

In SURMOUNT-5, slightly fewer people quit tirzepatide because of side effects. About 6% stopped for that reason, against about 8% on semaglutide. That gap is small, and no drug is gentler for everyone. Many women simply tolerate one better than the other.

Which one costs less: compounded, brand, or with insurance?

Semaglutide usually costs less, most clearly in compounded form. Compounded means a pharmacy mixes the drug itself, so it is not FDA-approved. At Fridays, for example, compounded semaglutide runs about $150 a month on a yearly plan. Tirzepatide on the same plan costs about $240.

Brand-name prices are closer. Through Lilly, Zepbound's starting dose costs about $300 a month. That is below the Wegovy pen's regular price of about $350. New Wegovy patients pay about $200 for each of their first two fills, through Dec 31, 2026.

• At a full dose, the order flips: Zepbound costs about $450 a month, and the Wegovy pen about $350.
• Zepbound's late-refill rule: from 7.5 mg, the $450 price needs a refill within 45 days. Otherwise it costs about $500–$700.
• Wegovy's highest dose: the 7.2 mg pen costs about $400 a month.
• The Wegovy pill: about $150 a month to start, about $300 at the higher doses. Tirzepatide has no pill.

For every route we have checked, see our semaglutide cost guide and tirzepatide cost guide.

Insurance changes the math. A commercial plan is one from an employer or one you buy yourself. If yours covers either drug for weight loss, the maker's savings card can bring it to as little as $25 a month. The card pays at most $100 a month, so a high copay leaves more for you to pay. See the Wegovy savings card and Zepbound savings card guides.

On Medicare, the GLP-1 Bridge charges $50 a month if you qualify. It covers Wegovy, Foundayo and the Zepbound KwikPen, but not Zepbound vials. Once both drugs cost the same, results and side effects should decide.

Which one is right for you? A pick for each profile

• You want the strongest average result and cost is secondary: tirzepatide has the best head-to-head evidence. Semaglutide's new 7.2 mg dose narrows the gap. Tirzepatide is still the surer bet for a bigger result.
• Budget decides: semaglutide is usually cheaper, compounded or brand. For many women, the gap between a 14% and a 20% average result matters less than about $100 a month.
• You have commercial insurance: start with whichever drug your plan covers. The savings card then brings either one to as little as $25 a month.
• You have Medicare: if you qualify, the GLP-1 Bridge charges $50 a month for Wegovy or the Zepbound KwikPen. Price no longer decides, so pick on results and side effects.
• Nausea has stopped you before: the trial gives tirzepatide a slight edge on tolerability. That varies from person to person.
• You want the longest track record: semaglutide has been sold longer. Ozempic came in 2017 and Wegovy in 2021, against 2022 for Mounjaro and 2023 for Zepbound.
• You want a pill: semaglutide is the only one of the two with an FDA-approved pill.

Semaglutide pill vs injection: does that change the comparison?

If you want to avoid needles, semaglutide has more to offer. The Wegovy pill is an FDA-approved oral semaglutide for weight loss. The Ozempic pill is the diabetes version. It has been sold under that name in the US since May 4, 2026, replacing Rybelsus.

Both pills come with a strict routine. You take the tablet on an empty stomach with a small sip of water, then wait before eating or taking anything else. Some telehealth companies also sell compounded semaglutide tablets that dissolve in the mouth. These are not FDA-approved.

Tirzepatide has no FDA-approved pill. Its structure doesn't survive digestion, so Zepbound and Mounjaro are shots only. Lilly's weight-loss pill, Foundayo, is a different drug called orforglipron. The FDA approved it on April 1, 2026. It acts only on the GLP-1 receptor, so it is not oral tirzepatide.

Can you switch from semaglutide to tirzepatide, or the reverse?

Yes. Clinicians make this switch routinely when weight loss stalls or side effects become hard to live with. There is no FDA dose conversion between the two drugs, so a switch is not a simple swap of numbers.

Most prescribers restart the new drug at its lowest dose, rather than matching where you left off. They time the change around each drug's weekly schedule so the two don't overlap. What a switch from Ozempic does to your bill, card and coverage is in Ozempic vs tirzepatide cost.

Is compounded semaglutide or tirzepatide the safer, more legitimate choice?

Neither has a broad compounding allowance anymore. Both were compounded at scale while the FDA listed them in shortage, and both shortages are over.

The FDA declared the tirzepatide shortage over in late 2024. Pharmacies then had a grace period to stop making copies. It ended in February 2025 for 503A pharmacies, which fill one patient's prescription at a time. It ended in March 2025 for 503B outsourcing facilities, which make larger batches. For semaglutide, the shortage ended in February 2025. Its grace periods ended in April and May 2025.

What remains for both drugs is a narrower path. A 503A pharmacy can still prepare the drug for one patient whose prescriber documents a clinical reason. On April 30, 2026, the FDA also proposed not adding semaglutide and tirzepatide to the list of bulk ingredients 503B facilities may use. As of October 2026, it has not made a final decision.

So the legitimacy question isn't really semaglutide versus tirzepatide. It is about the pharmacy and the provider. Look for a named, licensed pharmacy and clear sourcing. The provider should also explain how they document the medical need. Our compounded GLP-1 guide covers the rules and the providers in more detail.

Semaglutide vs tirzepatide for perimenopause and menopause weight gain

The weight shift of perimenopause has a hormonal driver. Falling estrogen makes the body respond less well to insulin and pushes fat toward the belly. Both drugs act on related pathways. They improve the insulin response and reduce appetite.

No trial has compared the two drugs in women in perimenopause or after menopause. SURMOUNT-5 is the best head-to-head evidence, and it wasn't designed around menopause. Tirzepatide's added GIP action might address insulin resistance a bit more directly. That is a theory, not a proven result in this group.